Trial Profile

A Pivotal Clinical Trial to Evaluate Intranasal Epinephrine Spray (BRYN-NDS1C) for Anaphylaxis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epinephrine (Primary)
Indications Anaphylaxis
Focus Pharmacodynamics; Pharmacokinetics; Registrational
Sponsors Bryn Pharma

Most Recent Events

24 Feb 2023 Results published in the Bryan Pharma media release.
24 Feb 2023 According to Bryn media release, positive results from this study were presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting in San Antonio, Texas, USA.
15 Feb 2023 According to a Bryn Pharma media release, results from this study will be presented as late breaking news at the American Academy of Allergy, Asthma and Immunology (AAAAI) annual meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com